TILT-123 licensing (ongoing phase 2, immunotherapy in platinum resistant ovarian cancer)

Tiltbio has a pipeline of multiple oncolytic viral therapies for solid tumors. The lead investigational asset, TILT-123, is a cytokine-armed oncolytic adenovirus currently in Phase II development in Europe and the U.S. both as a monotherapy and in combination with other immunotherapies like immune checkpoint inhibitors or tumor-infiltrating lymphocyte (TIL) therapy.

As the asset positively reaches maturity to engage into licensing discussions with Pharmaceutical companies able to support TILT-123's development into the market, we seek for a partner for local and global market.